FDA Revises Generic-Drug Application Policy
Since 1990, the FDA’s Office of Generic Drugs has always appraised submissions on a “first-in, first-reviewed” basis. Starting Wednesday, however, the agency said applications would be expedited for first generic drugs with no blocking patent.
“Ensuring that at least one generic medicine will be available to consumers when a brand’s patent expires is good news for consumers,”...
To view the full article, register now.